Filing Details
- Accession Number:
- 0001209191-12-041134
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2012-08-09 17:17:55
- Reporting Period:
- 2012-08-08
- Filing Date:
- 2012-08-09
- Accepted Time:
- 2012-08-09 17:17:55
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1012140 | Onyx Pharmaceuticals Inc | ONXX | Biological Products, (No Disgnostic Substances) (2836) | 943154463 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1197018 | Anthony N Coles | C/O Onyx Pharmaceuticals, Inc. 249 East Grand Ave. South San Francisco CA 94080 | President & Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2012-08-08 | 250,000 | $29.03 | 379,033 | No | 4 | M | Direct | |
Common Stock | Disposition | 2012-08-08 | 270,690 | $72.18 | 108,343 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | StockOption (Right to Buy) | Disposition | 2012-08-08 | 250,000 | $0.00 | 250,000 | $29.03 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
100,000 | 2018-03-30 | No | 4 | M | Direct |
Footnotes
- Reflects the forfeiture of 25,000 performance restricted stock units.
- The shares were sold at prices between $72.00 and $72.45. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- Twenty-Five percent of the shares subject to the option vested and became exercisable on March 31, 2009. The remaining shares vest and become exercisable at a rate of 1/48th per month thereafter.